Overview
NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission.
Last reviewed: 1 December 2021
Next review: We will review this decision if the company decides to make a submission.